Corpus Intelligence IC Memo — UNITED MEDICAL HEALTHWEST 2026-04-26 08:50 UTC
IC Memo — UNITED MEDICAL HEALTHWEST
Investment Committee Memorandum | LA | 20 beds | Grade C | EBITDA uplift $288K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

UNITED MEDICAL HEALTHWEST

CCN 193074 | JEFFERSON PARISH, LA | 20 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

UNITED MEDICAL HEALTHWEST is a 20-bed under-performing / distressed in JEFFERSON PARISH, LA with $3.7M in net patient revenue and a -39.1% operating margin. The hospital serves a payer mix of 32.3% Medicare, 1.0% Medicaid, and 66.8% commercial.

Thesis: Turnaround. Our ML models identify $288K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -39.1% to -31.4% (+772bps).

Net Revenue HCRIS$3.7M
Current EBITDA COMPUTED$-1.5M
Operating Margin COMPUTED-39.1%
Occupancy HCRIS45.9%
Revenue / Bed COMPUTED$186K
Net-to-Gross HCRIS67.1%
Distress Probability ML53.8%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
126
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -39.1% places it below the state median. Among 126 size-comparable peers (10-40 beds), the median margin is -2.1%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 126 hospitals in the comp set.

HospitalStateBedsRevenueMargin
UNITED MEDICAL HEALTHWEST (Target)LA20$3.7M-39.1%
SPECIALISTS HOSPITAL OF SHREVELA15$79.1M21.3%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%
AVALALA21$64.0M7.4%
BYRD REGIONAL HOSPITALLA39$61.1M2.5%
THE SPINE HOSPITAL OF LOUISIANLA23$57.4M35.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $288K (772bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Denial Rate Reduction12.0%6.5%$80K+215bp12mo
Net Collection Rate93.5%97.0%$78K+210bp18mo
Cost to Collect4.5%2.5%$75K+200bp12mo
A/R Days Reduction5200.0%3800.0%$45K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+26bp6mo

5. EBITDA Bridge

Denial Rate Reduction
$80K
Net Collection Rate
$78K
Cost to Collect
$75K
A/R Days Reduction
$45K
Clean Claim Rate
$10K
Total EBITDA Uplift$288K
Current EBITDA$-1.5M
+ RCM Uplift+$288K
Pro Forma EBITDA$-1.2M
Current Margin-39.1%
Pro Forma Margin-31.4%
WC Released (1x)$143K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.2M$-6.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.2M$-8.1M0.00x-100.0%
Bull Case9.0x11.0x$-2.0M$-7.9M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.0M$-9.2M0.00x-100.0%
Bear Case11.0x10.0x$-2.5M$-7.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.5M$-9.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 53.8% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 126 hospitals with 10-40 beds
  • Same-state prioritization (n=127)
  • Comp margins: P25=-14.8% / P50=-2.1% / P75=7.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.